Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a First-in-Man Study

Trial Profile

Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a First-in-Man Study

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; First in man
  • Sponsors Lepu Medical Technology (Beijing)
  • Most Recent Events

    • 23 Nov 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2019 to 1 Sep 2019.
    • 23 Nov 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 30 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top